It's unclear how he will impact biotech stocks. Evaluate the expected performance of Moderna (MRNA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom ...

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.